18-07-2018
miodrag ignjatovic / iStockphoto.com
US-based biopharmaceutical company AbbVie entered into a patent licensing agreement with generics company Mylan yesterday.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
AbbVie, Humira, Mylan, licence agreement, patent, patent agreement, Amgen, generics, biopharmaceuticals
Mylan fails to void MSD diabetes treatment patent at PTAB
11-05-2021
US Tax Court says Mylan can deduct patent litigation fees
29-04-2021
AbbVie and Momenta announce Humira patent licence agreement
08-11-2018
AbbVie enters Humira licensing deal with Fresenius Kabi
22-10-2018
AbbVie secures another Humira settlement
12-10-2018
AbbVie escalates Humira battle with Sandoz
13-08-2018
AbbVie and Alphabet company commit $1bn to collaboration
27-06-2018
AbbVie and Amgen settle Humira clash
29-09-2017
